Company Profile
Chunghwa Chemical Synthesis & Biotech provides the research, development, manufacturing, and sale of active pharmaceutical ingredients globally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DMF or COS, and API products specialty API immunosuppressants, including mycophenolate mofetil, rapamycin, and tacrolimus.
Its portfolio also includes derivative of rapamycin, such as everolimus, temsirolimus, zotarolimus, and biolimus, and echinocandin comprising caspofungin, micafungin, and anidulafungin. Additionally, it is also involved in contract manufacturing and research services.
It exports its products. Founded in 1964 and headquartered in New Taipei City, Taiwan, Chunghwa Chemical Synthesis & Biotech was formerly known as China Chemical Synthesis Industry Co., Ltd. before rebranding in January 2003.